Joy Yan, M.D., Ph.D., has served as our Chief Medical Officer since October 2020. Prior to joining us, she served as Senior Clinical Lead, Team Leader in Oncology at Bristol Myers Squibb (BMS), from April 2017 to October 2020, where she led the successful development of immuno-oncology assets (nivolumab and ipilimumab) from strategic planning through global submissions and approvals, including BMS’s first FDA pilot programs (RTOR, Project ORBIS, AAid). Previously, she served as Director of Oncology Clinical Research at Janssen Pharmaceutical, where she led daratumumab and anti-IL3R programs, from September 2016 to April 2017. Before Janssen, she served as Director of Clinical Development at Bayer AG, where she led Phase 1, 2, 3 studies evaluating different NMEs/MOAs including Radium-223, ADCs, Bi-specifics, and TKIs across many tumor types from October 2014 to September 2016. As our Chief Medical Officer, she has built our clinical development plans, assembled a highly-capable cross-functional drug development team, and overseen the advancement of our clinical programs. Dr. Yan completed her Ph.D. in biochemistry and molecular biology at Johns Hopkins University. She received her M.D. from China Medical University and did her residency and clinical fellowship at University of Washington.